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The active metabolite of leflunomide, A77 1726,
inhibits the production of prostaglandin E2,
matrix metalloproteinase 1 and interleukin 6 in
human fibroblast-like synoviocytes
D. Burger, N. Begue´-Pastor, S. Benavent, L. Gruaz,
M.-T. Kaufmann, R. Chicheportiche and J.-M. Dayer
Objectives. To investigate the effects of the active metabolite of leflunomide, A77
1726, on fibroblast-like synoviocytes. In rheumatoid arthritis (RA) synoviocytes
participate in tissue destruction by producing metalloproteinases (MMP), prost-
aglandin E2 (PGE2) and interleukin (IL) 6, which are involved in extracellular
matrix degradation, resorption of the mineral phase and osteoclast-mediated bone
resorption.
Methods. Human synoviocytes were stimulated with IL-1a or tumour necrosis
factor a (TNF-a) in the presence of A77 1726. Culture supernatants were analysed
for production of interstitial collagenase (MMP-1), tissue-inhibitor of metallo-
proteinases 1 (TIMP-1), PGE2 and IL-6. Total RNA was isolated and analysed
for steady-state levels of MMP-1, cyclooxygenase-2 (COX-2) and IL-6 mRNA.
Results. A77 1726 inhibited the production of PGE2 in synoviocytes activated by
TNF-a and IL-1a with median inhibitory concentrations (IC50) of 7 and 3 mM
respectively. In contrast, MMP-1 and IL-6 production was inhibited at high A77
1726 concentrations (> 10 mM), whereas TIMP-1 was not affected. The inhibition
of MMP-1 and IL-6 production was due to the known inhibitory effect of A77
1726 on pyrimidine synthesis, as it was reversed by the addition of uridine. This did
not apply to PGE2 production, which was inhibited via direct action of A77 1726
on COX-2, as shown by the increasing amount of substrate (arachidonic acid) in
the culture medium.
Conclusion. This study shows that some of the beneficial effect of leflunomide in
RA patients may be due to the inhibition of PGE2, IL-6 and MMP-1 production in
synoviocytes. This effect, coupled with its multiple inhibitory effects on T
lymphocyte functions, might account for the significant reduction in the rate of
disease progression in RA patients treated with leflunomide.
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Rheumatoid arthritis (RA) is characterized by the
thickening of synovial tissue and the destruction of
joint structure. The inflamed synovium thickens due
to the local proliferation of synovial cells and infiltra-
tion of inflammatory cells such as lymphocytes and
monocyte-macrophages w1x. We have established that
contact-mediated signalling of monocytes by stimulated
T lymphocytes is a potent mechanism which might
play a part in the persistence of chronic inflammation,
mainly in that it induces the production of large
amounts of the proinflammatory cytokines tumour
necrosis factor a (TNF-a) and interleukin (IL) 1b w2x.
IL-1 and TNF-a are potent inducers of metalloprotei-
nases (MMP), prostaglandin E2 (PGE2) and IL-6 in
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synoviocytes w3x. The activity of MMP is specifically
controlled by tissue inhibitors of metalloproteinases
(TIMP) w4x, whose production is increased by IL-6
w5x. Numerous observations support the premises that
in RA the resorption of the mineral phase is depen-
dent on PGE2, the extracellular matrix degradation is
mediated by proteolytic enzymes such as MMP, and the
resorption of periarticular bones is triggered by IL-6-
stimulated osteoclasts w6x. Together, these mechanisms
lead to tissue destruction and eventually invalidity in
patients w1, 7x.
Leflunomide (Arawa2) has been approved by the
Food and Drug Administration for treatment of RA
w8x. In vivo (in the cell), leflunomide is rapidly con-
verted into its active metabolite A77 1726 w9x. Although
the precise mode of action of leflunomide in vivo is still
elusive, in vitro A77 1726 reversibly inhibits dihydro-
orotate dehydrogenase (DHODH), the rate-limiting step
in the de novo synthesis of pyrimidines w10–12x. Indeed,
most of the effects of A77 1726 can be reversed by
supplying the product of DHODH activity, i.e. uridine,
to target cells. Leflunomide is a potent non-cytotoxic
inhibitor of the proliferation of stimulated B and T
lymphocytes in vitro, it is effective in several rodent
models of autoimmune diseases, and it prolongs graft
survival in animals w9, 13x. The latter effects have drawn
attention to the mechanisms of action of leflunomide
in immune cells, mainly T cells, in which it also blocks
TNF-mediated cellular responses by inhibiting nuclear
factor-kB (NFkB), a mechanism that depends on
pyrimidine biosynthesis w14, 15x. We showed previously
that A77 1726 inhibited the expression of monocyte-
activating factor at the surface of T lymphocytes.
This in turn decreased the activation of monocyte-
macrophages, thus inhibiting the production of IL-1b
and MMP by monocyte-macrophages w16x. In this
study, we address the question of the effect of A77
1726 on the production of PGE2, IL-6 and MMP-1 in
synoviocytes isolated from RA patients.
Materials and methods
Materials and reagents
The active metabolite of leflunomide, A771726, the kind gift
of Dr M. Herrmann (Aventis, Wiesbaden, Germany), was
made up as a 2 mM solution in water. Dulbecco’s modified
Eagle’s minimal essential medium (DMEM), phosphate-
buffered saline without Ca2+ and Mg2+ (PBS), fetal calf
serum (FCS), penicillin, streptomycin, L-glutamine and
TRIzol2 reagent were purchased from Gibco (Paisley, UK),
and arachidonic acid (AA) and uridine were purchased from
Sigma Fine Chemicals (St Louis, MO, USA). All other
reagents were of analytical grade or better. Human recombi-
nant IL-1a and TNF-a were obtained from Biogen (Geneva,
Switzerland) and Synergen (Boulder, CO, USA), respectively.
Synoviocyte cultures
Human synoviocytes were isolated by protease treatment of
surgical synovectomy specimens obtained from RA and
osteoarthritis patients and cultured in DMEM supplemented
with 10% FCS, 50 IUuml penicillin, 50 mguml streptomycin and
2 mM L-glutamine (medium) at 378C under an atmosphere of
5% CO2 w17, 18x. Synoviocytes (passages 2–5) were seeded into
96-well flat-bottom plates (23104 cellsuwell) and maintained for
48 h in medium before activation. Synoviocytes were cultured
for 2 h with the indicated concentration of A77 1726 before the
addition of optimal concentrations of TNF-a (10 nguml) or
IL-1a (250 pguml) in a final volume of 200 mluwell w17, 18x. When
required, uridine (50 or 200 mM) or AA (30 mM) was added
30 min before A77 1726. After 48 h, supernatants were
analysed for PGE2, MMP-1, TIMP-1 and IL-6 as described
elsewhere w17–19x. Results are expressed as mean"S.D. of at
least three experiments carried out with three different cultures
of synoviocytes.
mRNA analysis
Synoviocytes were seeded into 10 ml Petri dishes (23106
cellsudish) in complete DMEM. After 48 h the cells were
incubated for 30 min with or without 30 mM AA prior to the
addition of 1024 M A77 1726. After 2 h, cells were stimulated
with 10 nguml TNF-a or 250 pguml IL-1a for 3 and 18 h before
total RNA extraction by TRIzol according to the supplier’s
instructions (Life Technologies, Paisley, UK). Total RNA was
subjected to Northern blot (10 mg) and RNase protection
(2 mg) analysis as described previously w18, 20, 21x.
Results
A77 1726 inhibits PGE2, IL-6 and MMP-1 but not
TIMP-1 production in synoviocytes
To determine whether A77 1726 affects the production
of PGE2, IL-6, MMP-1 and TIMP-1, isolated syno-
viocytes were activated by an optimal concentration of
TNF-a (10 nguml) or IL-1a (250 pguml) in the presence
or absence of A77 1726. In human synoviocytes, which
did not produce significant amounts of PGE2 in the
absence of stimulus, TNF-a and IL-1a induced the
production of 190"76 and 291"130 nguml PGE2
respectively (Fig. 1A). PGE2 production was completely
abolished in the presence of 1024 M A77 1726. Synovio-
cytes constitutively produced MMP-1 (1.9"1.6 mguml,
n=5) and its inhibitor TIMP-1 (3.0"1.9 mguml).
Depending on the synoviocyte donorupreparation,
TNF-a and IL-1a increased MMP-1 production to
3.8"1.7 and 3.1"1.5 mguml respectively, and the
induced but not the basal production of MMP-1 was
inhibited by 1024 M A77 1726 (Fig. 1B). In contrast,
TIMP-1 production was neither increased by TNF-a or
IL-1a nor affected by A77 1726 (Fig. 1C). IL-6
production by synoviocytes was marked in the absence
of stimulus, reaching 7"5 nguml (Fig. 1D). This basal
production was increased by IL-1a and TNF-a to
346"100 and 129"78 nguml respectively. In the pre-
sence of A77 1726, the IL-6 production induced by
IL-1a and TNF-awas inhibited by 47 and 63% respectively
(Fig. 1D).
To ascertain whether the inhibitory effect of A77 1726
on PGE2, IL-6 and MMP-1 production would occur at
concentrations possibly reached in treated patients, the
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inhibitory effect of serial concentrations of A77 1726 was
assessed. A77 1726 diminished PGE2 production by
synoviocytes in a dose-dependent way; PGE2 production
was abolished at 1024 M A77 1726 and inhibited by 100
and 99% upon stimulation by TNF-a and IL-1a
respectively (Fig. 2A and B). The apparent median
inhibitory concentration (IC50) was 7 and 3 mM A77
1726 when synoviocytes were stimulated by TNF-a and
IL-1a respectively. In contrast, the induction of MMP-1
production was inhibited at high A77 1726 concentra-
tions only, and no inhibition was observed at concentra-
tions< 531025 M A77 1726 (Fig. 2C and D). Similarly,
the induced production of IL-6 was only inhibited by
concentrations > 531025 M A77 1726 (Fig. 2E and F).
Confirming results shown in Fig. 1, TIMP-1 production
was not affected by A77 1726 (Fig. 2G and 2H),
demonstrating that the marked inhibition of cytokine-
induced production of PGE2, IL-6 and MMP-1 at high
A77 1726 concentration was not due to a putative
cytotoxic effect of the drug.
A77 1726 inhibited PGE2, MMP-1 and IL-6
through different mechanisms
In order to assess whether the inhibition of PGE2,
MMP-1 and IL-6 production was due to the well-
described in vitro inhibition of pyrimidine synthesis by
A77 1726, uridine was used to reverse the inhibitory
effect of A77 1726. In contrast with the inhibition
of MMP-1 and IL-6 production that was completely
reversed by uridine (Fig. 3), the inhibition of PGE2
production by A77 1726 was not reversed by either
50 mM (data not shown) or 200 mM uridine (Fig. 3). This
suggests that the inhibition of MMP-1 and IL-6 pro-
duction was due to the inhibition of DHODH, i.e. the
inhibition of pyrimidine synthesis, another mechanism
involved in the inhibition of PGE2 production.
Because A77 1726 has been reported to inhibit the
activity of cyclooxygenase (COX) 2 directly w22, 23x, the
inhibition of PGE2 production by A77 1726 was
assessed in the presence of an excess of the enzyme
substrate AA. As shown in Fig. 4A and B, AA (30 mM)
FIG. 1. A77 1726 inhibits the production of PGE2, MMP-1
and IL-6 but not TIMP-1 in human synoviocytes. Synoviocytes
were preincubated for 2 h with 1024 M A77 1726 (A77) before
the addition of 10 nguml TNF-a or 250 pguml IL-1a. After
48 h, supernatants were analysed for PGE2 (A), MMP-1 (B),
TIMP-1 (C) and IL-6 (D). Results are expressed as percentage
of total production in the absence of inhibitor as mean"S.D.,
for three experiments with three different synoviocyte cultures.
FIG. 2. The inhibition of PGE2 and MMP-1 production by
A77 1726 is dose-dependent. Synoviocytes were preincubated
for 2 h with the indicated concentration of A77 1726 before the
addition of 250 pguml IL-1a (A, C, E, G) or 10 nguml TNF-a
(B, D, F, H). After 48 h, supernatants were analysed for PGE2
(A and B), MMP-1 (C and D), IL-6 (E and F) and TIMP-1
(G and H), as described in the legend of Fig. 1.
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did not induce a detectable amount of PGE2, suggesting
that COX-1 expression by synoviocytes was poor. AA
increased the production of PGE2 induced by IL-1a and
TNF-a, which reached 743"221 and 406"210 nguml
respectively. AA shifted the IC50 to 20 mM A77 1726
(Fig. 4A and B), implying that the inhibitor was dis-
placed from the enzyme and consequently that A77
1726 interacted directly with COX-2. In the presence of
AA, neither the production of MMP-1 nor its inhibi-
tion by A77 1726 was affected (not shown). Upon syno-
viocyte stimulation by IL-1a and TNF-a, AA increased
basal IL-6 production slightly (1.3-and 1.7-fold respec-
tively, to 340"26 and 100"13 nguml). Although AA
did not reverse the inhibition by A77 1726 of IL-6
production induced by IL-1a (Fig. 4C), it partially
reversed the inhibition when synoviocytes were stimu-
lated by TNF-a (Fig. 4D). This suggests that PGE2
might enhance cytokine-induced IL-6 production, a
phenomenon that was more pronounced, i.e. detectable,
when cytokine stimulation was low. Indeed, the pro-
duction of IL-6 induced by TNF-a was three times
lower than that induced by IL-1a, suggesting that IL-1a
overcame the enhancing effect of PGE2 on IL-6
production. This was confirmed by the use of indo-
methacin, which inhibits the production of PGE2.
Indomethacin abolished the production of PGE2
induced by both IL-1a and TNF-a (Fig. 5A). Because
MMP-1 production was not affected, its inhibition by
A77 1726 cannot result from the diminution of PGE2
FIG. 3. Uridine reversed the inhibition by A77 1726 of MMP-1
and IL-6 but not PGE2 production. When indicated (+),
synoviocytes were preincubated for 30 min with 200 mM
uridine before the addition of 1024 M A77 1726. After 2 h
incubation with A77 1726, cells were activated by TNF-a (A,
C, E) or IL-1a (B, D, F) for 48 h. Supernatants were analysed
for PGE2 (A and B), MMP-1 (C and D) and IL-6 (E and F), as
indicated in the legend of Fig. 1.
FIG. 4. Differential effect of arachidonic acid (AA) on the
inhibitory activity of A77 1726. Synoviocytes were preincubated
for 30 min in the presence (squares) or absence (circles) of
30 mM AA before being cultured as described in the legend of
Fig. 1. Supernatants were analysed as indicated in the legend
of Fig. 1. In the absence of A77 1726, PGE2 production was
743"221 and 140"83 nguml in the presence of IL-1a plus
AA and of IL-1a alone, respectively, and 406"210 and
76"13 nguml in the presence of TNF-a plus AA and of
TNF-a alone, respectively. In the absence of inhibitor, IL-6
production was 340"26 and 260"22 nguml in the presence of
IL-1a plus AA and of IL-1a alone, respectively, and 100"13
and 60"6 nguml in the presence of TNF-a plus AA and of
TNF-a alone, respectively.
FIG. 5. Inhibition of MMP-1 production does not depend on
the inhibition of PGE2 production. Synoviocytes were pre-
incubated for 1 h in the presence (u) or absence (I) of 5 mguml
indomethacin prior to activation with 250 pguml IL-1a or
10 nguml TNF-a for 48 h. Supernatants were analysed for
PGE2 (A), MMP-1 (B) and IL-6 (C).
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concentration in the medium (Fig. 5B). However, the
specific inhibition of PGE2 production by indomethacin
decreased IL-6 production by 20 and 42% when
synoviocytes were stimulated by IL-1a and TNF-a
respectively, demonstrating that the production of
IL-6 due to endogenously produced PGE2 was higher
when cells were stimulated by TNF-a than by IL-1a.
To confirm that different mechanisms were involved
in the inhibition of PGE2, MMP-1 and IL-6 in syno-
viocytes, the effect of A77 1726 on steady-state levels
of mRNAs for COX-2, MMP-1 and IL-6 was assessed
by either Northern blot or RNase protection analysis.
COX-2 mRNA was not expressed in synoviocytes,
whether unstimulated or cultured in the presence of
AA (Fig. 6A and B). Upon stimulation for 3 h by
IL-1a or TNF-a, COX-2 mRNA was expressed. Levels
of MMP-1 mRNA were high in unstimulated syno-
viocytes, and 2- to 2.5-fold increase was observed in the
presence of cytokines (Fig. 6C and F). However, in the
presence of A77 1726, AA, or both, there were no
changes in the steady-state level of either COX-2 or
MMP-1 mRNA, as shown by Northern blot analysis
(Fig. 6A–C). Similarly, after 15 h of incubation the
steady-state level of MMP-1 mRNA was not affected
by A77 1726, uridine, or both, as shown by RNase
protection assay (Fig. 6D and F). This contrasted
with the fact that MMP-1 production induced by
cytokines was indeed inhibited by A77 1726 (Figs 1
and 2) and that uridine reversed this inhibition (Fig. 4).
The steady-state level of IL-6 mRNA was inhibited by
A77 1726, an effect that was reversed by uridine
(Fig. 6D and E). This confirms that A77 1726 inhibited
IL-6 production through the inhibition of DHODH, i.e.
the inhibition of pyrimidine synthesis.
Discussion
The salient result of this study is that leflunomide
modulates the production of destructive factors by
synoviocytes. Indeed, the active metabolite of lefluno-
mide, A77 1726, inhibits PGE2, IL-6 and MMP-1
production in synoviocytes. Although the inhibition of
MMP-1 and IL-6 production only occurred at high
A77 1726 concentrations, PGE2 production was inhibi-
ted by A77 1726 with an IC50 <10 mM when either
IL-1a or TNF-a was used as a stimulus. This effect was
not reversed by uridine, contrary to other inhibitory
activities of A77 1726 that have been described w9, 15x,
which have an IC50 in the same range. However, the
inhibition of MMP-1 and IL-6 production was fully
reversed by uridine, demonstrating that the inhibition
of MMP-1 and IL-6 expression was due to the block-
ade of pyrimidine synthesis. The inhibition of MMP-1
and IL-6 production was observed in the presence of
0531025 M A77 1726, roughly equal to the maximal
plasma concentration in treated patients, i.e. around
50 mM w24x. This suggests that part of the beneficial
effects of A77 1726 in RA patients might be due to the
inhibition of PGE2, MMP-1 and IL-6 production in
synoviocytes.
High concentrations of A77 1726 are required to
inhibit the induced production of MMP-1 and IL-6.
However, even at these high drug concentrations, the
production of TIMP-1 was not affected by A77 1726,
showing that high levels of A77 1726 did not display
cytotoxicity towards synoviocytes. Furthermore, from
the premise that TIMP-1 production remained unchan-
ged upon A77 1726 treatment, it follows that the drug
tends to favour factors that counteract the enzymatic
FIG. 6. Northern blot and RNase protection analysis of the steady-state level of mRNAs for COX-2, IL-6 and MMP-1. When
indicated, synoviocytes were cultured for 30 min with 30 mM arachidonic acid (AA) or 200 mM uridine before the addition of
1024 M A77 1726. After 2 h incubation with A77 1726 (A77), cells were stimulated or not with 250 pguml IL-1a or 10 nguml TNF-a
for 3 h (A–C) or 18 h (D–F). (A) Northern blot autoradiography and (B and C) densitometric analysis of autoradiographic
data shown in A normalized for densitometry of GAPDH (glyceraldehyde-3-phosphate dehydrogenase) mRNA=1.
(D) Autoradiography of RNase protection gel and (E and F) densitometric analysis of autoradiographic data shown in
D normalized for densitometry of GAPDH mRNA=1.
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degradative processes. This is reminiscent of previous
results we obtained about the effect of A77 1726 on
the expression of monocyte-stimulating factors on the
surface of activated T lymphocytes w16x. Indeed, in that
study we showed that in the presence of 1025 M A77
1726 the molar ratios of IL-1 receptor agonistuIL-1b
and TIMP-1uMMP-1 produced by the monocytic cells
were increased around 4- and 2-fold, respectively. This
demonstrated that in the T cellumonocyte-macrophage
system also, A77 1726 tends to favour the inhibition of
proinflammatory and matrix-destructive factors over
that of anti-inflammatory factors and metalloproteinase
inhibitors, thus interfering with both inflammation and
tissue destruction.
A77 1726 inhibited the activity of COX-2 directly.
Indeed, an excess of exogenous COX-2 substrate (AA)
increased the cytokine-induced production of PGE2 in
the absence of A77 1726 and increased the IC50 of A77
1726 2- to 6-fold. The direct inhibition of COX-2 by
A77 1726 has been described in other cellular systems.
A77 1726 inhibits the activity of COX-1 and -2 isolated
from sheep, although with an IC50 of 742 and 2766 mM
respectively, suggesting that A77 1726 is a weak
inhibitor of PGE2 synthesis w22x. This low inhibitory
potency was attributed in part to the premise that A77
1726 displays extremely high levels of binding to serum
proteins w25x. More recently, A77 1726 was shown to
inhibit COX-2 activity in the presence of 10% FCS in
two cell lines, J774.2 murine macrophages and A549
human epithelial cancer cells, with IC50 values com-
parable to those observed here, i.e. in the micromolar
range w23x. Although A77 1726 has been shown to
inhibit PGE2 production directly in several types of
cell, this is the first observation of such inhibition
occurring in synoviocytes, which are primarily involved
in tissue degradation processes in RA. A77 1726 has
been shown to inhibit both COX-1 and COX-2 activity
w22x. It is, however, very unlikely that it inhibits a
putative COX-1 activity in synoviocytes as there was
no constitutive production of PGE2 in these cells and
AA did not induce any detectable PGE2 production in
the absence of cytokine. Therefore, as A77 1726-
inhibition of PGE2 production was observed in the
presence of 10% FCS in the micromolar range, it might
occur in vivo and thus account for part of the beneficial
effect of leflunomide in RA. New drugs which specifi-
cally inhibit COX-2 but not COX-1 activity have been
shown to display anti-inflammatory activities in RA
patients w26, 27x. A77 1726 is not a specific inhibitor of
COX-2, as it has also been shown to inhibit COX-1 w22x.
However, it displays weak inhibitory activity compared
with other COX inhibitors with IC50 values in the
micromolar range w22x. However, we cannot rule out
the possibility of synergism or an additive effect due to
the inhibition of PGE2 when leflunomide is administered
together with other NSAIDs.
Although A77 1726 inhibited MMP-1 production, it
did not decrease the level of MMP-1 mRNA, suggesting
that the inhibition of MMP-1 production occurred at
a post-transcriptional level. This contrasts with data
showing that A77 1726 blocks NFkB activation in
T cells, MMP-1 promoter containing an NFkB-
responsive element w14, 28x. Whether A77 1726 inhibits
NFkB nuclear translocation in synoviocytes remains to
be determined. A77 1726 might inhibit MMP-1 produc-
tion because of decreased production of pyrimidine
sugars w29x. Indeed, pyrimidine sugars are important in
the synthesis of the N-glycans that are present on at least
some MMP-1s w30, 31x. Thus, considering its inhibitory
effect on DHODH, A77 1726 could decrease the con-
centration of one or the other of the pyrimidine sugars,
triggering misglycosylation of MMP-1, which in turn
could hamper its production.
The efficiency of leflunomide in the treatment of
RA patients might be due to the fact that it acts at
several levels of the inflammatory cascade w32x. Indeed,
in addition to the inhibition of production of PGE2,
MMP-1 and IL-6 in synoviocytes, A77 1726 diminishes
the ability of stimulated T cells to induce the pro-
duction of proinflammatory cytokines in monocyte-
macrophages w16x, a mechanism highly relevant to
chronic inflammation w2, 33–35x. Inhibiting the induc-
tion of cytokine production in monocyte-macrophages
by A77 1726 in turn lowers the levels of inducers of
metalloproteinases, IL-6 and PGE2 in synoviocytes,
and because this affects PGE2 synthesis directly in
the latter cells the production of inflammatory factors
is decreased still further. Together, these effects
might account for the significant reduction in the rate
of disease progression in RA patients treated with
leflunomide w36–38x.
In conclusion, this study demonstrates that lefluno-
mide may affect functions of stromal cells involved in
tissue destruction in RA. This suggests that leflunomide
not only acts on several types of cells involved in the
inflammatory cascade but also interferes with different
intracellular processes, and may thus display broad
efficacy in RA.
Acknowledgements
The authors are grateful to Dr M. L. Herrmann
(Aventis, Wiesbaden, Germany) for his generous gift of
A77 1726, and to Mrs Roswitha Rehm for skilful
reading of the manuscript. This work was supported in
part by a grant from the Swiss National Science
Foundation (320-068286.02), the Hans Wilsdorf
Foundation and a grant from the Swiss Society for
Multiple Sclerosis.
References
1. Krane SM, Goldring SR, Dayer JM. Interactions among
lymphocytes, monocytes and other synovial cells in
rheumatoid synovium. In: Pick E, Landy M, eds.
Lymphokines, Vol. 7. New York: Academic Press,
1982:75–136.
94 D. Burger et al.
2. Burger D. Cell contact-mediated signaling of monocytes by
stimulated T cells: a major pathway for cytokine induction.
Eur Cytokine Netw 2000;11:346–53.
3. Dayer JM, Arend WP. Cytokines and growth factors.
In: Kelley WN, Harris ED Jr, Ruddy S, Sledge CS, eds.
Textbook of rheumatology. Philadelphia: W.B. Saunders,
1997:267–86.
4. Nagase H, Woessner JF Jr. Matrix metalloproteinases.
J Biol Chem 1999;274:21491–4.
5. Lotz M, Guerne PA. Interleukin-6 induces the synthesis
of tissue inhibitor of metalloproteinases-1uerythroid
potentiating activity (TIMP-1uEPA). J Biol Chem 1991;
266:2017–20.
6. Matsuda T, Hirano T. IL-6. In: Oppenheim JJ, Feldmann
M eds. Cytokine reference. New York: Academic Press,
2000:DOI: 10.1006urwcy.2000.06001.
7. Harris ED. Enzymes responsible for joint destruction.
In: Harris ED, ed. Rheumatoid arthritis. Philadelphia: W.B.
Saunders, 1997:168–75.
8. Fox RI, Herrmann ML, Frangou CG et al. Mechanism
of action for leflunomide in rheumatoid arthritis. Clin
Immunol 1999;93:198–208.
9. Herrmann ML, Schleyerbach R, Kirschbaum BJ.
Leflunomide: an immunomodulatory drug for the treat-
ment of rheumatoid arthritis and other autoimmune
diseases. Immunopharmacology 2000;47:273–89.
10. Bartlett RR, Brendel S, Zielinski T, Schorlemmer HU.
Leflunomide, an immunorestoring drug for the therapy
of autoimmune disorders, especially rheumatoid arthritis.
Transplantation Proc 1996;28:3074–8.
11. Cherwinski HM, Byars N, Ballaron SJ, Nakano GM,
Young JM, Ransom JT. Leflunomide interferes with
pyrimidine nucleotide biosynthesis. Inflamm Res 1995;
44:317–22.
12. Williamson RA, Yea CM, Robson PA et al. Dihydro-
orotate dehydrogenase is a target for the biological
effects of leflunomide. Transplantation Proc 1996;
28:3088–91.
13. Breedveld FC, Dayer JM. Leflunomide: mode of action
in the treatment of rheumatoid arthritis. Ann Rheum Dis
2000;59:841–9.
14. Manna SK, Aggarwal BB. Immunosuppressive lefluno-
mide metabolite (A77 1726) blocks TNF-dependent
nuclear factor-kB activation and gene expression. J
Immunol 1999;162:2095–2.
15. Manna SK, Mukhopadhyay A, Aggarwal BB. Lefluno-
mide suppresses TNF-induced cellular responses: effects on
NF-kB, activator protein-1, c-Jun N-terminal protein
kinase, and apoptosis. J Immunol 2000;165:5962–9.
16. De´age V, Burger D, Dayer JM. Exposure of T lymphocytes
to leflunomide but not to dexamethasone favors the
production by monocytic cells of interleukin-1 receptor
antagonist and the tissue-inhibitor of metalloproteinases-1
over that of interleukin-1b and metalloproteinases. Eur
Cytokine Netw 1998;9:663–8.
17. Burger D, Chicheportiche R, Giri JG, Dayer JM. The
inhibitory activity of human interleukin-1 receptor antago-
nist is enhanced by type II interleukin-1 soluble receptor
and hindered by type I interleukin-1 soluble receptor. J Clin
Invest 1995;96:38–41.
18. Burger D, Rezzonico R, Li JM, Modoux C, Welgus HG,
Dayer JM. Imbalance between interstitial collagenase
(MMP-1) and tissue inhibitor of metalloproteinases-1
(TIMP-1) in synoviocytes and fibroblasts upon direct
contact with stimulated T lymphocytes: involvement of
membrane-associated cytokines. Arthritis Rheum 1998;
41:1748–59.
19. Vey E, Zhang JH, Dayer J-M. IFN-gamma and
1,25(OH)2D3 induce on THP-1 cells distinct patterns of
cell surface antigen expression, cytokine production, and
responsiveness to contact with activated T cells. J Immunol
1992;149:2040–6.
20. Rezzonico R, Burger D, Dayer JM. Direct contact between
T lymphocytes and human dermal fibroblasts or synovio-
cytes down-regulates types I and III collagen production
via cell-associated cytokines. J Biol Chem 1998;
273:18720–8.
21. Jungo F, Dayer JM, Modoux C, Hyka N, Burger D. IFN-b
inhibits the ability of T lymphocytes to induce TNF-a and
IL-1b production in monocytes upon direct cell–cell
contact. Cytokine 2001;14:272–82.
22. Curnock AP, Robson PA, Yea CM et al. Potencies of
leflunomide and HR325 as inhibitors of prostaglandin
endoperoxide H synthase-1 and -2: comparison with
nonsteroidal anti-inflammatory drugs. J Pharmacol Exp
Ther 1997;282:339–47.
23. Hamilton LC, Vojnovic I, Warner TD. A771726, the active
metabolite of leflunomide, directly inhibits the activity of
cyclo-oxygenase-2 in vitro and in vivo in a substrate-
sensitive manner. Br J Pharmacol 1999;
127:1589–96.
24. Weinblatt ME, Kremer JM, Coblyn JS et al. Pharmaco-
kinetics, safety, and efficacy of combination treatment with
methotrexate and leflunomide in patients with active
rheumatoid arthritis. Arthritis Rheum 1999;42:1322–8.
25. Lucien J, Dias VC, LeGatt DF, Yatscoff RW.
Blood distribution and single-dose pharmacokinetics of
leflunomide. Ther Drug Monit 1995;17:454–9.
26. Schnitzer TJ, Truitt K, Fleischmann R et al. The safety
profile, tolerability, and effective dose range of rofecoxib in
the treatment of rheumatoid arthritis. Phase II Rofecoxib
Rheumatoid Arthritis Study Group. Clin Ther
1999;21:1688–702.
27. Luong BT, Chong BS, Lowder DM. Treatment options for
rheumatoid arthritis: celecoxib, leflunomide, etanercept, and
infliximab. Ann Pharmacother 2000;34:743–60.
28. Vincenti MP, Coon CI, Brinckerhoff CE. Nuclear factor-
kBup50 activates an element in the distal matrix
metalloproteinase 1 promoter in interleukin-1b-stimulated
synovial fibroblasts. Arthritis Rheum 1998;41:1987–94.
29. Abeijon C, Hirschberg CB. Topography of glycosylation
reactions in the endoplasmic reticulum. Trends Biochem
Sci 1992;17:32–6.
30. Saarinen J, Welgus HG, Flizar CA, Kalkkinen N, Helin J.
N-glycan structures of matrix metalloproteinase-1 derived
from human fibroblasts and from HT-1080 fibrosarcoma
cells. Eur J Biochem 1999;259:829–40.
31. Wilhelm SM, Eisen AZ, Teter M, Clark SD, Kronberger
A, Goldberg G. Human fibroblast collagenase: glycosyla-
tion and tissue-specific levels of enzyme synthesis. Proc
Natl Acad Sci USA 1986;83:3756–60.
32. Dayer JM, Feige U, Edwards III CK, Burger D. Anti-
interleukin-1 therapy in rheumatic diseases. Curr Opin
Rheumatol 2001;13:170–6.
33. McInnes IB, Leung BP, Liew FY. Cell–cell interactions
in synovitis. Interactions between T lymphocytes and
synovial cells. Arthritis Res 2000;2:374–8.
34. Parry SL, Sebbag M, Feldmann M, Brennan FM. Contact
with T cells modulates monocyte IL-10 production. Role of
T cell membrane TNF-a. J Immunol 1997;158:3673–81.
Effects of leflunomide on synoviocytes 95
35. Burger D. Meeting report: Cell contact interactions
in rheumatology. The Kennedy Institute for Rheuma-
tology, London, UK, 1–2 June 2000. Arthritis Res 2000;
2:472–6.
36. Strand V, Cohen S, Schiff M et al. Treatment of
active rheumatoid arthritis with leflunomide compared
with placebo and methotrexate. Leflunomide Rheuma-
toid Arthritis Investigators Group. Arch Intern Med
1999;159:2542–50.
37. Smolen JS, Kalden JR, Scott DL et al. Efficacy and safety
of leflunomide compared with placebo and sulphasalazine
in active rheumatoid arthritis: a double-blind, randomised,
multicentre trial. European Leflunomide Study Group.
Lancet 1999;353:259–66.
38. Emery P, Breedveld FC, Lemmel EM et al. A comparison
of the efficacy and safety of leflunomide and methotrexate
for the treatment of rheumatoid arthritis. Rheumatology
2000;39:655–65.
96 D. Burger et al.
